Group 1 - Sanofi has announced a definitive agreement to acquire Dynavax Technologies Corporation for $15.50 per share, totaling approximately $2.2 billion in equity value [1][3] - The acquisition aligns with Sanofi's strategy to expand its presence in adult immunization, particularly through Dynavax's hepatitis B vaccine, HEPLISAV-B, which is the only two-dose adult hepatitis B vaccine approved in the US [2][3] - The deal has been unanimously approved by Dynavax's board and is expected to close in the first quarter of 2026, with no impact on Sanofi's financial guidance for 2025 [3] Group 2 - Analysts have a positive outlook on Sanofi, with a 12-month price target reflecting more than 26% upside from the current level, and a recent Hold rating with a price target of $57 from TD Cowen [4]

Investment Rating - The report does not explicitly state an investment rating for the biopharmaceutical industry, but it suggests a positive outlook based on upcoming catalysts and potential drug approvals. Core Insights - The biopharmaceutical sector is expected to see significant developments in 2026, with multiple domestic drugs anticipated to report key clinical data. This includes drugs from companies like Betta Pharmaceuticals, Hutchison China MediTech, and CanSino Biologics, which are expected to read out critical clinical data in 2026 [3][21]. - The report emphasizes that the long-term theme for the innovative drug sector is international expansion, with several sub-themes to focus on, including overseas business development (BD) licensing, key clinical trials, and unexpected overseas sales growth [3][18]. Summary by Sections Weekly New Drug Market Review - From December 22 to December 28, 2025, the top five gainers in the new drug sector were Dongyao Pharmaceutical (+23.15%), Beihai Kangcheng (+19.27%), Junshengtai (+16.41%), Shiyao Group (+6.95%), and Ailis (+5.78%). The top five losers were Gakos (-16.11%), Jiahe Biotech (-10.29%), Laika Pharmaceuticals (-9.33%), Yunding Xinyao (-8.98%), and Yongtai Biotech (-6.94%) [1][14]. Weekly Focused Stocks - The report suggests focusing on several stocks with high overseas expansion potential, including: 1. Companies with MNC certification and high overseas volume certainty: Sanofi, United Pharmaceuticals, and Kelun-Biotech. 2. Companies with overseas data catalysts: Betta Pharmaceuticals, Hutchison China MediTech, and InnoCare Pharma. 3. Potential heavyweights for overseas MNC licensing: Junshi Biosciences, Shiyao Group, and Yifang Biotech. 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat loss and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][18]. Weekly New Drug Approval & Acceptance Status - This week, 23 new drug or new indication applications were approved in China, and 10 new drug or new indication applications were accepted [4][19]. Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 99 new drug clinical applications were approved, and 64 new drug clinical applications were accepted [5][24]. Key Domestic Market Events - Notable events include: 1. Xiansheng Zhaoming announced a global exclusive licensing agreement with Ipsen for an ADC drug, potentially worth up to $1.06 billion. 2. He Yu Pharmaceuticals received approval for its CSF-1R selective small molecule inhibitor. 3. Tongyi Pharmaceuticals announced a licensing agreement for a peptide conjugate drug for prostate cancer, with potential payments totaling around $2 billion [10]. Key Overseas Market Events - Significant overseas events include: 1. Novo Nordisk received FDA approval for a 25mg oral semaglutide tablet for weight loss. 2. Sanofi announced a cash acquisition agreement for Dynavax Technologies Corporation, valued at approximately $2.2 billion. 3. Agios Pharmaceuticals announced FDA approval for an oral PK activator for treating α or β thalassemia in adult patients [11].

Group 1: Market Overview - The Christmas week began with positive momentum from Big Tech, particularly driven by Nvidia's H200 chip, although gains were limited as traders sought safe-haven assets [1] - The U.S. economy showed stronger-than-expected growth at 4.3% for Q3, while durable goods orders fell by 2.2% in October [1] - The S&P 500 Index achieved a record close during the Christmas Eve session, and all three major indexes posted healthy weekly gains despite initial concerns about a "Santa Claus" rally [2] Group 2: Drug Industry Developments - Biohaven's treatment for major depressive disorder did not meet its primary objective in a phase 2 study, impacting its stock performance [3] - Novo Nordisk received FDA clearance for its GLP-1 pill, indicating a positive development for the company [3] - Vanda Pharmaceuticals is seeking approval for its antibody treatment for psoriasis, which could enhance its market position [3] Group 3: Technology Sector Highlights - Nvidia continues to attract bullish sentiment despite its stock's volatility, reflecting strong investor confidence [4] - Tesla reached new record highs, showcasing its ongoing growth and market interest [4] - Micron Technology extended its record-breaking performance, indicating robust demand in the semiconductor sector [4] Group 4: Upcoming Economic Reports - The upcoming week will feature key economic reports, including November's pending home sales and the minutes from the December FOMC meeting, which could influence market sentiment [5]

Market Overview - The U.S. stock market opened with mixed performance on December 26, 2025, as traders returned from the Christmas holiday, with major indexes showing cautious movements after a robust week [1] - The S&P 500 (SPX) edged up 0.1%, the Dow Jones Industrial Average (DJIA) was largely unchanged, and the Nasdaq Composite (COMP) rose 0.2% [2] Major Market Indexes Performance - On December 24, the DJIA surged 0.6%, or 288.75 points, closing at a record high of 48,731.16, while the Nasdaq Composite finished up 0.2% at 23,613.31, driven by gains in AI-related companies [3] - The S&P 500 gained 0.3% to reach a new all-time closing high of 6,932.05, touching an intraday record of 6,937.32 [3] Economic Data - Initial jobless claims for the week ended December 24 decreased by 10,000 to 214,000, lower than the consensus estimate of 221,000, while continuing claims increased by 38,000 to 1.923 million [4] Upcoming Market Events - Key economic releases to watch include the Case-Shiller Home Price Index for October and Pending Home Sales for November, along with the December FOMC meeting minutes [5] Key Company News and Stock Movers - Nvidia (NVDA) shares dipped 0.3% but later rebounded by 1.1% after announcing a $20 billion all-cash acquisition of assets from Groq [6] - Nike Inc. (NKE) shares surged 4.6% after Apple CEO Tim Cook purchased $3 million worth of stock, with shares up 0.5% in recent trading [7] - Dynavax Technologies Corp. (DVAX) jumped 38.2% after Sanofi announced its acquisition in a deal valued at approximately $2.2 billion [8] - Intel Corp. (INTC) shares fell 0.5% after Nvidia ceased testing manufacturing chips using Intel's production process [9] - Micron Technology Inc. (MU) rose 3.8%, and Snowflake (SNOW) is in talks to acquire Observe for around $1 billion [10] Broader Market Trends - Gold and silver prices reached new record highs, reflecting demand for safe-haven assets, while WTI crude oil futures dipped slightly [11] - The U.S. 10-year Treasury yield decreased to 4.12%, and Bitcoin was trading around $89,000 [11] - The CBOE Volatility Index (VIX) decreased by 3.8%, indicating reduced market apprehension [11]

Market Overview - U.S. stock markets resumed normal trading hours on December 26, 2025, following the Christmas holiday, with major indices closing at record highs due to strong AI sector performance and positive economic data [1][3] - The Dow Jones Industrial Average (DJIA) rose 0.6% to 48,731.16, the S&P 500 (SPX) gained 0.3% to 6,932.05, and the Nasdaq Composite (IXIC) increased 0.2% to 23,613.31 [3] Premarket Activity - In premarket trading, Dow Jones futures were down approximately 0.1% to 0.2%, while S&P 500 futures showed a fractional decline of 0.03% to 0.1% lower; Nasdaq 100 futures edged slightly higher by 0.00% to 0.02% [4] Corporate Earnings and Developments - Nvidia (NVDA) shares rose 0.6% to 0.7% in premarket trading following the announcement of a $20 billion acquisition of assets from AI chip startup Groq, aimed at strengthening its position in the AI inference sector [8] - Nike (NKE) shares surged 4.6% on December 24, supported by a regulatory filing revealing Apple CEO Tim Cook's $3 million purchase of Nike shares [9] - Micron Technology (MU) shares rose 3.8% on December 24 and continued to gain 2% in premarket trading, contributing to a nearly 22% increase this month due to optimistic earnings forecasts [13] - Dynavax Technologies Corp. (DVAX) shares soared 38.2% after Sanofi announced its acquisition of the company for approximately $2.2 billion [13] - Intel Corp. (INTC) shares fell 0.5% after reports that Nvidia has ceased testing its 18A production process with Intel [13] - Snowflake (SNOW) is reportedly in advanced discussions to acquire AI-native startup Observe for around $1 billion, which would be its largest acquisition to date [13] - Prudential Financial (PRU) shares rebounded after a planned share buyback program of up to $1 billion was announced [13] - Biohaven Pharmaceutical (BHVN) shares dropped 13.4% in premarket trading after its depression drug failed in a clinical trial [13] - DENSO Corporation announced a joint development agreement with MediaTek Inc. to accelerate next-generation automotive system-on-chips [13] - Infineon Technologies achieved a milestone with all global operations now supplied with 100% green electricity [13]

Market Performance - The S&P 500 reached an intraday record high of 6,921.42 points, surpassing its previous peak from October, driven by broad sector gains and investor optimism regarding potential interest rate cuts from the Federal Reserve next year [1] - The Dow Jones Industrial Average increased by 167.50 points, or 0.35%, to 48,610.95, while the S&P 500 gained 10.24 points, or 0.15%, to 6,920.24, and the Nasdaq Composite saw a slight decline of 2.48 points, or 0.01%, to 23,558.35 [5] Economic Indicators - The U.S. economy experienced its fastest growth in two years during the third quarter, although consumer confidence worsened in December and factory production remained flat in November, which tempered the economic outlook [2] - New applications for U.S. jobless benefits unexpectedly fell last week, indicating steady labor market conditions [2] Sector Highlights - Micron Technology's stock surged by 4% following a strong forecast, contributing to the overall gains in the market [3] - Bank stocks also supported the S&P 500, with financials rising by 0.4% to a new peak [3] - Dynavax Technologies experienced a significant increase of 38.5% after Sanofi announced plans to acquire the company for approximately $2.2 billion [8] Market Trends - The recent gains in U.S. stocks have led to expectations of a "Santa Claus rally," a seasonal trend where the S&P 500 typically gains in the last five trading days of the year and the first two in January [4] - The bull market, which began in October 2022, remains intact, supported by optimism around AI, anticipated rate cuts, and a resilient economy, with all three main indexes poised for their third consecutive yearly gain [6]

新华社上海12月26日电（记者王默玲、周蕊、桑彤）免签政策持续扩容，"中国游"热潮席卷全球；离境退税便捷高效，"中国购"热度持续攀 升；外资企业加速布局，"投资中国"信心坚定。2025年，人流、商流、资金流在此交汇，形成一股强大的"中国引力"。 "中国游"旺 夜晚的黄浦江畔，美国游客莱娜正举着手机视频通话，兴奋地向家人展示上海外滩的风光。一边是陆家嘴灯光璀璨的都市天际线，一边是外 滩别具风情的万国建筑群。"上海太迷人了！"莱娜告诉记者，"过境免签政策让我来了一次说走就走的中国游，这是我2025年做的最正确的决 定。" 作为国际消费中心城市，上海的"中国购"热度尤为凸显。记者从国家税务总局上海市税务局获悉，2025年1月至11月，上海办理离境退税的境 外旅客数量同比增长156.3%，退税商品销售额和退税额同比增长约80%。 这样的消费热度绝非上海独有。2025年截至11月底，广东省内海关共验核离境退税申请单9.3万票，离境退税商品金额17.5亿元，分别是去年 同期的7.5倍和2倍，实现大幅增长；深圳市2025年前11个月办理离境退税5.6万笔，同比增长13倍，离境退税商品退税销售额同比增长2.4倍，"即 买即退 ...

Core Insights - Tianjing Biopharma has signed a collaboration agreement with Zhijiang Laboratory Technology Holdings to develop next-generation long-acting innovative biologics, including growth hormones, aimed at providing more convenient treatment options for patients [1][5]. Company Overview: Tianjing Biopharma - Tianjing Biopharma focuses on innovative therapies for autoimmune diseases, tumor immunology, and metabolic diseases, with a differentiated dual-tier innovative drug pipeline [6]. - The first tier includes three products (Fizetuzumab, Eitan Growth Hormone α, and Idaglutide α) that have entered the product listing acceptance stage, while four additional innovative products are in the registration clinical stage or about to start Phase III clinical trials [6]. - The second tier consists of First-in-Class innovative drug projects based on the AntibodyPLUS platform, which are about to enter Phase I clinical trials or initiate clinical applications [6][7]. - The company is accelerating the internationalization of its innovative drug pipeline and integrating R&D, production, and product listing processes in China through collaborations with partners like Jichuan Pharmaceutical, Shiyao Group, and Sanofi [7]. Company Overview: Zhijiang Laboratory Technology Holdings - Zhijiang Laboratory Technology Holdings was established on September 27, 2020, to accelerate the application of technological achievements in the field of intelligent computing and to serve the development of the digital economy and emerging industries [8]. - The company has a registered capital of 100 million yuan and is located in the Future Technology City AI Town in Yuhang District, Hangzhou [8]. - Zhijiang Holdings is dedicated to providing high-quality full-chain services for the transformation and industrialization of technological achievements, including basic services like policy promotion and project due diligence, as well as value-added services such as concept verification and financing [8]. Collaboration Insights - The collaboration will leverage Zhijiang Laboratory's AI-driven research discovery platform, BioDeepDiscovery (BDD), while Tianjing Biopharma will contribute its extensive R&D experience, biological data, and preclinical research capabilities [2][6]. - The partnership aims to combine the strengths of both companies to accelerate drug development processes, particularly in exploring long-acting innovative biologics across multiple therapeutic areas [2][6].

Investment Rating - The report maintains a "Buy" rating for the overseas education sector, particularly highlighting New Oriental as a key player [10]. Core Insights - The overseas education sector is experiencing improved operational efficiency and accelerated profit margin expansion, with New Oriental expected to report a revenue of $1.165 billion for Q2 FY26, representing a year-on-year growth of 12.2% [5][10]. - The report anticipates a significant increase in non-GAAP net profit for New Oriental, projected at $63 million, which is a 77.8% increase year-on-year, with a non-GAAP net profit margin of 5.4%, expanding by 2 percentage points [5][10]. Summary by Sections 1. Overseas Education - **Market Review**: The education index rose by 2.8% in the week of December 19-25, outperforming the Hang Seng Index by 1.8 percentage points, with a year-to-date increase of 13.1% [4]. - **Company Update**: New Oriental's revenue is expected to reach $1.165 billion, with the education business (including cultural tourism) contributing $957 million, a growth of 11% year-on-year [5][10]. - **Study Abroad Business**: The revenue from study abroad exam training and consulting is projected to decline by 3% to $242 million, reflecting a slowdown in growth due to high base effects from the previous year [2][5]. - **New Business Growth**: New business segments, including K9 competency training and learning machine services, are expected to grow by 21% to $364 million, driven by differentiated offerings for primary and secondary education [3][6]. - **Operating Profit Margin Improvement**: Despite a slowdown in high-margin study abroad business, the increase in competency business margins is expected to offset this. The non-GAAP operating profit margin is projected to expand by approximately 2 percentage points to 4.7% [6][10]. 2. Overseas Pharmaceuticals - **Market Review**: The Hang Seng Healthcare Index saw a slight increase of 0.02%, underperforming the Hang Seng Index by 1.24 percentage points [12]. - **Key Events**: Notable transactions include Sanofi's $2.2 billion acquisition of vaccine company Dynavax, which has a marketed hepatitis B vaccine and a promising shingles vaccine candidate [14]. - **Investment Recommendations**: The report suggests focusing on innovative drug companies with active business development opportunities and clinical progress in key pipelines, including companies like BeiGene and Innovent Biologics [15]. 3. Overseas Social Services - **Ctrip's Q3 Performance**: Ctrip reported a 16% year-on-year revenue increase to $18.4 billion, with strong performance across various business segments, particularly in international OTA platforms [17]. - **Tongcheng Travel's Q3 Performance**: Tongcheng Travel's revenue grew by 10% to $5.5 billion, with a notable increase in accommodation and core OTA business revenues [18]. - **Key Focus**: The report highlights potential growth in the outbound travel sector and the importance of hotel management services as additional growth drivers [19].

Market Outlook - The market experienced a phenomenal year in 2025, with the S&P 500 achieving 41 record high closes and a total return of approximately 18% [2] - The bull market reached its 3-year anniversary, and expectations for 2026 include another bull market year with increased volatility and double-digit growth [2] - Key sectors expected to perform well include AI, AI infrastructure, aerospace and defense, biotech, and energy companies, driven by increased capital expenditure over the past two years [2] Diversification Trends - Analysts believe 2026 will emphasize diversification, with the influence of the "Mag Seven" on the S&P 500 weakening [3] - The contribution of the "Mag Seven" to total returns has decreased from 62% two years ago to around 44% for 2025 [3] - Earnings expansion and increased spending are expected to drive double-digit growth, while valuation multiples are anticipated to remain stable [3] Affordable Stocks Analysis - A list of the 15 Best Affordable Stocks was curated using various financial databases, focusing on stocks trading below a forward P/E of 15 with expected upside of over 25% [6] - Hedge fund sentiment was also considered, as imitating top stock picks from hedge funds has historically outperformed the market [7] Company Highlights - **Sanofi (NASDAQ:SNY)**: - Forward P/E Ratio: 10.61, with a 12-month analyst upside potential of 26.14% [8][9] - Recently announced acquisition of Dynavax Technologies for $2.2 billion, enhancing its adult immunization portfolio [9][11] - The acquisition is expected to close in Q1 2026 and will not impact financial guidance for 2025 [11][12] - **PVH Corp. (NYSE:PVH)**: - Forward P/E Ratio: 6.32, with a 12-month analyst upside potential of 30.61% [13] - Experienced a decline of over 21% since its fiscal Q3 2025 earnings release, yet analysts maintain a positive outlook [13] - Fiscal Q3 2025 revenue grew by 1.74% year-over-year to $2.29 billion, exceeding expectations [15] - EPS of $2.83 also surpassed expectations, driven by the execution of the PVH+ plan and growth in key categories [15][16]